Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
Coronavirus
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call

  • Adam Feuerstein

By Adam Feuerstein Feb. 2, 2021

Reprints
Vertex Pharmaceuticals - sunset
Bill Sikes/AP

Who (or what) is Vertex Pharmaceuticals going to buy?

The question — asked many different ways by analysts — dominated the company’s year-end earnings conference call on Monday evening.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

People with terminal cancer need to know they are…
People with terminal cancer need to know they are dying. Doctors shouldn’t withhold that information
Your questions on the new Covid vaccine boosters answered
Your questions on the new Covid vaccine boosters answered
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Pharmalittle: Illumina faces more challenges after winning FTC case;…
Pharmalittle: Illumina faces more challenges after winning FTC case; Novo Nordisk buys Forma Therapeutics
Illumina wins case against FTC in bid to hold…
Illumina wins case against FTC in bid to hold onto early cancer detection company Grail
Listen: The anti-aging research boom, the Godfather of biotech,…
Listen: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

Recommended Stories